Eyedeal Achieves NMPA Approval for Groundbreaking xPIB Aspheric IOL

Xi’an, China, Oct 07, 2025 – Eyedeal Medical Technology (Xi’an), a leader in ophthalmic innovation, today announced that its revolutionary xPIB Aspheric Intraocular Lens (IOL) has received market approval from China’s National Medical Products Administration (NMPA) as an innovative product on September 29. This milestone culminates 12 years of dedicated research, development, and a successful clinical trial conducted in China.

The xPIB Aspheric IOL represents a monumental leap forward in cataract and refractive surgery, being the first IOL introduced in many years to feature an entirely new material platform.

“This approval is not just a regulatory milestone; it’s a validation of over a decade of perseverance and our commitment to redefining the standard of care for patients in China,” said Mr. Guangxu Guo, CEO of Eyedeal. “The xPIB material fundamentally changes the possibilities in IOL design and performance.”

The core of this innovation is the novel xPIB material, which features a unique structure with no cleavage groups. This key attribute provides exceptional long-term stability and biocompatibility, as the material is resistant to degradation.

Dr. Yune Zhao, Principal Investigator for the xPIB clinical study, Vice President of the Eye Hospital & School of Ophthalmology and Optometry at Wenzhou Medical University, highlighted the clinical benefits: “The xPIB material’s absence of glistening and significantly reduced postoperative inflammatory response, combined with a high refractive index and high Abbe number, will provide patients with optimum visual accuracy and long-term optical clarity. Furthermore, its exceptional elongation of over 250% allows us to implant a 6.5mm optic through a micro-incision, enabling a smoother recovery with less visual disturbance.”

The NMPA approval of the xPIB IOL also establishes a critical foundation for utilizing the xPIB material in other ophthalmic applications. This approval provides the base for using the xPIB material in other applications that the company is currently developing in collaboration with partners, aiming to unlock the full potential of this platform technology across the field.

Furthermore, the NMPA’s recognition as an innovative product not only validates the xPIB platform but also establishes a robust clinical and regulatory foundation. This milestone is expected to significantly streamline and accelerate the approval process for the xPIB IOL in other international markets, facilitating its global journey.

“Our research team set out to solve fundamental limitations in IOL materials. The xPIB platform opens a new chapter for IOL advancement,” said Yin Yang, SVP of R&D. “With this regulatory milestone achieved, we are now poised to explore broader applications through strategic partnerships.”

This NMPA approval paves the way for Eyedeal to bring this transformative technology to surgeons and patients across China, offering a new level of visual outcomes and surgical experience.